Skip to Content

Fenofibrate Dosage

Applies to the following strength(s): 48 mg ; 145 mg ; 54 mg ; 160 mg ; 67 mg ; 200 mg ; 134 mg ; 40 mg ; 120 mg ; 43 mg ; 130 mg ; 30 mg ; 90 mg ; 50 mg ; 150 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Hyperlipidemia

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIa (Elevated LDL)

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Dyslipidemia

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IV (Elevated VLDL)

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Usual Adult Dose for Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Usual Adult Dose for Hypertriglyceridemia

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Renal Dose Adjustments

Mild to moderate renal dysfunction:
-Capsules: 50 mg orally once a day
-Micronized Capsules: 30 to 67 mg orally once a day
-Tablets: 40 to 54 mg orally once a day; Triglide(R): Not recommended.

Comments:
-Doses may be increased after evaluation of the effects on renal function and lipid levels at the initial dose chosen.

Severe renal dysfunction: Contraindicated

Liver Dose Adjustments

Active liver disease (including primary biliary cirrhosis and unexplained persistent liver function abnormalities): Contraindicated

Dose Adjustments

Elderly: Due to the higher incidence of renal impairment in this patient population, dose selection should be based on renal function; monitor renal function during therapy; Lofibra(R) micronized capsules should be initiated and limited to 67 mg/day

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Contraindicated

Other Comments

Administration advice:
-May be taken with food to increase absorption.
-Swallow capsules and tablets whole; do not break, open, crush, dissolve, or chew.
-Take at least 1 hour before or 4 to 6 hours after a bile acid binding resin.

Storage requirements:
-Protect from light and moisture.
-Triglide(R): Dispense in original bottle.

General:
-Patients should be placed on an appropriate lipid-lowering diet prior to receiving this drug and should continue this diet throughout treatment.
-This drug has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.
-Markedly elevated levels of serum TG (e.g. greater than 2000 mg/dL) may increase the risk of developing pancreatitis; the effect of this drug on reducing this risk has not been adequately studied.
-An attempt should be made to control serum lipids with non-pharmacologic methods prior to initiating drug therapy (e.g., diet, exercise, control of medical problems, dose reduction of medications known to exacerbate hypertriglyceridemia, etc.).

Monitoring:
-Hematologic: Monitor RBC and WBC counts periodically during the first 12 months of therapy.
-Hepatic: Measure liver function at baseline and periodically thought-out therapy.
-Metabolic: Periodically measure lipid levels and adjust dose accordingly.
-Renal: Monitor renal function in patients with renal impairment or those at risk for renal insufficiency.

Patient advice:
-Report immediately any muscle pain, tenderness, or weakness, onset of abdominal pain, or any other new symptoms.
-Talk to your health care provider if you are pregnant, planning to become pregnant, or breastfeeding.

Hide